The Role of Single-Use Systems in Cell and Gene Therapies
As cell and gene therapies (CGT) continue to advance, single-use systems have become essential for maintaining the safety and effectiveness of these intricate biological products. These systems not only improve sterility but also simplify manufacturing processes, playing a vital role in both the initial and final stages of production, and ensuring that these potentially life-saving therapies remain reliable and high-quality for patients. Read following considerations for manufacturers in the area of cell & gene therapies. Most suitable areas of single-use systems in CGT manufacturing processes Ensuring that cell and gene therapy products are shipped at cold temperatures with robust controls is, if anything, even more important for this class of products than it is for more traditional biopharmaceutical products because they are complex biological systems and you really don't want to take any risks of them being disrupted during storage and shipment. The use of single-use systems is particularly important for cell and gene products because maintaining sterility and the aseptic nature of processing is so critical. For a cell therapy product you can't do sterile filtration at the end of your manufacturing process, so integrating aseptic processing into every stage of manufacturing is far more critical compared to, for example, monoclonal antibodies where you have the benefit of being able to do a sterile filtration step at the end. Different applications of single-use systems in cell & gene therapies There are robust applications both upstream and downstream. For example, in an autologous CAR-T process, the initial leukapheresis product that you're taking from the patient and shipping to your manufacturing site is a critical starting material that's entering into your process at the very upstream part of your manufacturing process. There is high potential to improve the reliability, reproducibility, and robustness of that shipping process using secondary packagings, such as the RoSS shell. Because it is a patient-specific raw material it is incredibly precious (in fact, close to irreplaceable), so it is critical that it not be damaged or destroyed during shipping and that its quality is maintained at the highest level. Similarly, once the CAR-T product has been manufactured, it needs to be returned from the manufacturing site to the point of care for the patient, and arguably it is even more precious at this stage since a patient life hangs in the balance. Therefore, ensuring the highest possible control of shipping conditions to maintain product quality during that return shipment is also critical. There are pretty robust use cases for single-use system products at both the most upstream and the furthest downstream steps of cell and gene therapy manufacturing processes. Why are single-use technologies established as a standard in gene therapy? First, since gene therapy processes are younger, they've had the benefit of being able to adopt these newer technologies during their development processes. Given that, and combined with the relative importance of aseptic processing as I described earlier, Therefore, developers tend to gravitate towards single-use systems in designing their processes. An additional factor is that cell and gene therapy processes are typically not operating at the very large scales of some more traditional processes. For example, typical monoclonal antibody facilities are operating at a scale of hundreds to thousands of liters, whereas many cell and gene therapy processes operate at a fraction of that scale, making those processes more amenable to single-use systems as opposed to, for example, the large stainless stirred tanks of older manufacturing processes. Chicken or egg: did cell & gene therapies boost the use of single-use technologies or vice versa? Newer, more modern biopharmaceutical processes that are being developed have already been migrating towards single-use systems. And cell and gene therapies are building on the back of that. There are a lot of things that are different about cell and gene therapy manufacturing, but there are also a lot of things that are the same. For example, to make a monoclonal antibody, you grow cells, harvest the cells, and purify the antibody. Thinking about cell therapy manufacturing, the process is very similar: you grow your cells using, in many cases very similar processes, and the only difference is that now the cells themselves are your product rather than the protein that they've been harnessed to produce. And for a viral process it's even more similar because you're just harnessing the cells to produce your virus instead of a protein. So the basics of cell cultures are the same across all types of processes and the difference is basically, what are you harvesting at the other end of that process and purifying and formulating and filling? Therefore, cell and gene therapy manufacturing processes very much benefit from the learnings of best practices around cell cultures that have already been developed in other areas of biopharmaceutical manufacturing. Considerations for manufacturers when implementating or ramping-up single-use systems Manufacturers should be sure that they understand what the ultimate goal is with respect to their manufacturing process. This can take different forms for different products, but let’s consider the case of an allogeneic cell therapy product. For an allogeneic product in early clinical trials, you may only need to be manufacturing product for tens of patients in a year, but you want to make sure that the manufacturing processes that you have developed has a clear path to scalability to where you want to be at your commercial scale, which, depending on the indication that you’re going after, could be thousands or even tens of thousands of patients. It has a few different implications: one is, at what scale does your manufacturing process ultimately need to be able to operate in order to make it manageable in terms of the number of manufacturing lots you need to make per year for that product? Typically you may be aiming for something in the low tens of manufacturing lots per year, so if you're aiming to make product for tens of thousands of patients, that can be a pretty large scale manufacturing process that you need to be able to achieve. You need to think about what that vessel looks like and is there an appropriate scale down model that you can be using today to enable you to get to that with minimal comparability risk and technical risk for scale up. And then the other thing that comes into play for cell therapy products in that calculation is making sure that your cells are able to undergo the number of cell divisions that is required to achieve that scale, without impacting the critical quality attributes of your product. So even when you're not manufacturing at that large scale in an early clinical stage, you need to be sure that you are still testing the robustness of your process with late passage cells so that you don't hit an unexpected roadblock later when you scale up. More Solutions for Advanced Therapies
READ MORE
